JP7002446B2 - Cd3結合ポリペプチド - Google Patents
Cd3結合ポリペプチド Download PDFInfo
- Publication number
- JP7002446B2 JP7002446B2 JP2018513821A JP2018513821A JP7002446B2 JP 7002446 B2 JP7002446 B2 JP 7002446B2 JP 2018513821 A JP2018513821 A JP 2018513821A JP 2018513821 A JP2018513821 A JP 2018513821A JP 7002446 B2 JP7002446 B2 JP 7002446B2
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- binding
- domain
- amino acid
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562221190P | 2015-09-21 | 2015-09-21 | |
US62/221,190 | 2015-09-21 | ||
PCT/US2016/052942 WO2017053469A2 (en) | 2015-09-21 | 2016-09-21 | Cd3 binding polypeptides |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2018531000A JP2018531000A (ja) | 2018-10-25 |
JP2018531000A6 JP2018531000A6 (ja) | 2018-12-13 |
JP2018531000A5 JP2018531000A5 (ru) | 2019-11-07 |
JP7002446B2 true JP7002446B2 (ja) | 2022-03-04 |
Family
ID=58387225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018513821A Active JP7002446B2 (ja) | 2015-09-21 | 2016-09-21 | Cd3結合ポリペプチド |
Country Status (19)
Country | Link |
---|---|
US (1) | US11352426B2 (ru) |
EP (1) | EP3352760A4 (ru) |
JP (1) | JP7002446B2 (ru) |
KR (1) | KR20180053322A (ru) |
CN (1) | CN108367004B (ru) |
AU (1) | AU2016326449A1 (ru) |
BR (1) | BR112018005573A2 (ru) |
CA (1) | CA2999138A1 (ru) |
CO (1) | CO2018004094A2 (ru) |
EA (1) | EA201890613A1 (ru) |
HK (2) | HK1251175A1 (ru) |
IL (1) | IL258202B2 (ru) |
MX (1) | MX2018003292A (ru) |
MY (1) | MY197562A (ru) |
PH (1) | PH12018500520A1 (ru) |
SG (1) | SG10202002577XA (ru) |
UA (1) | UA126278C2 (ru) |
WO (1) | WO2017053469A2 (ru) |
ZA (1) | ZA201802440B (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180069067A (ko) | 2015-10-30 | 2018-06-22 | 엔비이-테라퓨틱스 아게 | 안티-ror1 항체 |
KR20180101554A (ko) | 2016-01-20 | 2018-09-12 | 더 스크립스 리서치 인스티튜트 | Ror1 항체 조성물 및 관련 방법 |
SG10202102846SA (en) | 2016-09-21 | 2021-04-29 | Aptevo Res & Development Llc | Cd123 binding proteins and related compositions and methods |
EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
WO2019016381A1 (en) * | 2017-07-20 | 2019-01-24 | Nbe-Therapeutics Ag | MULTISPECIFIC ANTIBODY PRODUCT BINDING TO DIFFERENT ROR1 EPITOPES |
EP3655439A1 (en) | 2017-07-20 | 2020-05-27 | Aptevo Research and Development LLC | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
MX2020001212A (es) | 2017-08-07 | 2020-03-20 | Nbe Therapeutics Ag | Conjugados anticuerpo-farmaco a base de antraciclina que tienen alta tolerabilidad in vivo. |
JP7387611B2 (ja) | 2017-09-22 | 2023-11-28 | ウーシー バイオロジクス アイルランド リミテッド | 新規二重特異性ポリペプチド複合体 |
AU2018337142A1 (en) * | 2017-09-22 | 2020-05-07 | Wuxi Biologics Ireland Limited. | Novel bispecific CD3/CD19 polypeptide complexes |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
KR102353568B1 (ko) * | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편 |
CA3164385A1 (en) | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Formulations for protein therapeutics |
US20230151102A1 (en) * | 2020-01-13 | 2023-05-18 | Aptevo Research And Development Llc | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
WO2022042488A1 (en) * | 2020-08-24 | 2022-03-03 | Epimab Biotherapeutics (Hk) Limited | Anti-ror1 antibodies and related bispecific binding proteins |
KR20230117379A (ko) | 2020-12-01 | 2023-08-08 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | 이종이량체 psma 및 cd3-결합 이중특이적 항체 |
AU2022276523A1 (en) | 2021-05-21 | 2024-01-18 | Aptevo Research And Development Llc | Dosing regimens for protein therapeutics |
WO2023288191A1 (en) * | 2021-07-13 | 2023-01-19 | University Of Washington | Multiple de novo designed protein binding proteins |
WO2023061419A1 (en) * | 2021-10-12 | 2023-04-20 | Concept To Medicine Biotech Co., Ltd. | Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins |
WO2023169419A1 (en) * | 2022-03-09 | 2023-09-14 | Antengene (Hangzhou) Biologics Co., Ltd. | Novel anti-cd3 antibodies and uses thereof |
WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014072888A1 (en) | 2012-11-07 | 2014-05-15 | Pfizer Inc. | Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates |
WO2014106602A1 (en) | 2013-01-02 | 2014-07-10 | Glenmark Pharmaceuticals S.A. | Antibodies that bind to tl1a and their uses |
JP2014517844A (ja) | 2011-05-21 | 2014-07-24 | マクロジェニクス,インコーポレーテッド | ヒト及び非ヒトcd3に結合可能なcd3結合分子 |
Family Cites Families (483)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3927193A (en) | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
US4460561A (en) | 1980-03-03 | 1984-07-17 | Goldenberg M David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
US4460559A (en) | 1980-03-03 | 1984-07-17 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4468457A (en) | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4818709A (en) | 1983-01-21 | 1989-04-04 | Primus Frederick J | CEA-family antigens, Anti-CEA antibodies and CEA immunoassay |
US4460459A (en) | 1983-02-16 | 1984-07-17 | Anschutz Mining Corporation | Sequential flotation of sulfide ores |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4624846A (en) | 1983-07-29 | 1986-11-25 | Immunomedics, Inc. | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4782840A (en) | 1984-03-02 | 1988-11-08 | Neoprobe Corporation | Method for locating, differentiating, and removing neoplasms |
US4935495A (en) | 1984-12-21 | 1990-06-19 | Oncogen | Monoclonal antibodies to the L6 glycolipid antigenic determinant found on human non-small cell lung carcinomas |
US4906562A (en) | 1984-12-21 | 1990-03-06 | Oncogen | Monocolonal antibodies and antigen for human non-small cell lung carcinomas |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US5955315A (en) | 1985-11-19 | 1999-09-21 | Schering Corporation | Nucleic acids encoding human interleukin-4 |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US6121424A (en) | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
US4932412A (en) | 1986-12-18 | 1990-06-12 | Immunomedics, Inc. | Intraoperative and endoscopic tumor detection and therapy |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
HUT53672A (en) | 1988-02-25 | 1990-11-28 | Gen Hospital Corp | Quick immunoselective cloning process |
US4861579A (en) | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
CA2006408A1 (en) | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
US5217713A (en) | 1988-12-27 | 1993-06-08 | Takeda Chemical Industries, Ltd. | Cytotoxic bispecific monoclonal antibody, its production and use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
US5098833A (en) | 1989-02-23 | 1992-03-24 | Genentech, Inc. | DNA sequence encoding a functional domain of a lymphocyte homing receptor |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5897861A (en) | 1989-06-29 | 1999-04-27 | Medarex, Inc. | Bispecific reagents for AIDS therapy |
CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
US5980896A (en) | 1989-06-30 | 1999-11-09 | Bristol-Myers Squibb Company | Antibodies reactive with human carcinomas |
EP0487587A1 (en) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
ATE152174T1 (de) | 1989-09-20 | 1997-05-15 | Abbott Lab | Verfahren zur herstellung von fusionsproteinen |
US6018031A (en) | 1989-10-20 | 2000-01-25 | Trustees Of Dartmouth College | Binding agents specific for IgA receptor |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
EP0512064B1 (en) | 1990-01-23 | 1997-06-18 | Tanox Biosystems, Inc. | Extracellular segments of human ige immunoglobulin anchoring peptides and antibodies specific therefor |
CA2077348A1 (en) | 1990-03-02 | 1991-09-03 | Stephen D. Gillies | Antibody constructs with enhanced binding affinity |
US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
US20030219446A1 (en) | 1990-03-26 | 2003-11-27 | Bristol-Myers Squibb Company | Ligand for CD28 receptor on B cells and methods |
GB9009106D0 (en) | 1990-04-23 | 1990-06-20 | 3I Res Expl Ltd | Processes and intermediates for synthetic antibody derivatives |
EP0537293A4 (en) | 1990-07-02 | 1993-09-08 | Bristol-Myers Company | Ligand for cd28 receptor on b cells and methods |
ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
JPH06506358A (ja) | 1991-03-28 | 1994-07-21 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ | ナチュラルキラー細胞に特異的なdnaおよびアミノ酸配列 |
JPH06508133A (ja) | 1991-05-31 | 1994-09-14 | ジェネンテク,インコーポレイテッド | Hivに関連した免疫性の血小板減少性紫斑病の治療 |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
ATE170562T1 (de) | 1991-06-27 | 1998-09-15 | Bristol Myers Squibb Co | Ctl4a rezeptor, ihn enthaltenden fusionsproteine und deren verwendungen |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
DE69207603T2 (de) | 1991-08-16 | 1996-09-12 | Vical Inc | Zusammensetzung und verfahren zur behandlung von zystischer fibrose |
US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
US6472510B1 (en) | 1992-02-14 | 2002-10-29 | Bristol-Myers Squibb Company | CD40 receptor ligands |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
CA2137361A1 (en) | 1992-06-10 | 1993-12-23 | W. French Anderson | Vector particles resistant to inactivation by human serum |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
EP0586002B1 (en) | 1992-08-18 | 2000-01-19 | CENTRO de IMMUNOLOGIA MOLECULAR | Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them |
PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
ZA936260B (en) | 1992-09-09 | 1994-03-18 | Smithkline Beecham Corp | Novel antibodies for conferring passive immunity against infection by a pathogen in man |
US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
WO1994009034A1 (en) | 1992-10-12 | 1994-04-28 | Agen Limited | Clot directed anticoagulant, process for making same and methods of use |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
PL174721B1 (pl) | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
US6482919B2 (en) | 1993-02-01 | 2002-11-19 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5597707A (en) | 1993-04-15 | 1997-01-28 | Bristol-Myers Squibb Company | Tumor associated antigen recognized by the murine monoclonal antibody L6, its oligonucleotide sequence and methods for their use |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
US5795572A (en) | 1993-05-25 | 1998-08-18 | Bristol-Myers Squibb Company | Monoclonal antibodies and FV specific for CD2 antigen |
US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
JP2991499B2 (ja) | 1993-09-02 | 1999-12-20 | トラスティーズ・オブ・ダートマス・カレッジ | 抗gp39抗体およびその用途 |
US5869049A (en) | 1993-09-02 | 1999-02-09 | Trustees Of Dartmouth College | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
JPH09503759A (ja) | 1993-09-22 | 1997-04-15 | メディカル リサーチ カウンシル | 抗体のリターゲッティング |
GB9412166D0 (en) | 1993-09-22 | 1994-08-10 | Medical Res Council | Retargetting antibodies |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
DE69533544T2 (de) | 1994-01-11 | 2006-02-23 | Dyax Corp., Cambridge | Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten |
US6380369B1 (en) | 1994-01-27 | 2002-04-30 | Human Genome Sciences, Inc. | Human DNA mismatch repair proteins |
JPH09509054A (ja) | 1994-02-01 | 1997-09-16 | アメリカ合衆国 | 抗体部分および非抗体部分を含む融合タンパク質 |
AU692239B2 (en) | 1994-03-07 | 1998-06-04 | Medarex, Inc. | Bispecific molecules having clinical utilities |
PT699237E (pt) | 1994-03-17 | 2003-07-31 | Merck Patent Gmbh | Fvs de cadeia anti-egfr e anticorpos anti-egfr |
AU694222B2 (en) | 1994-05-02 | 1998-07-16 | Bernd Groner | Bifunctional protein, preparation and use |
US5945273A (en) | 1997-06-03 | 1999-08-31 | Human Genome Sciences, Inc. | Human oxalyl-coa decarboxylase |
US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
WO1996006941A1 (de) | 1994-08-26 | 1996-03-07 | Hoechst Aktiengesellschaft | Gentherapie von erkrankungen, die durch das immunsystem bedingt sind, mit hilfe eines zellspezifischen zellzyklusregulierten wirkstoffes |
US6380169B1 (en) | 1994-08-31 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Metal complex containing oligonucleoside cleavage compounds and therapies |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US6383814B1 (en) | 1994-12-09 | 2002-05-07 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US6706484B1 (en) | 1995-08-18 | 2004-03-16 | Morphosys Ag | Protein/(poly)peptide libraries |
GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
US5866330A (en) | 1995-09-12 | 1999-02-02 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
WO1997013529A1 (en) | 1995-10-13 | 1997-04-17 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Immunotoxin containing a disulfide-stabilized antibody fragment |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6379966B2 (en) | 1999-02-26 | 2002-04-30 | Mirus Corporation | Intravascular delivery of non-viral nucleic acid |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
GB2310894A (en) | 1996-03-06 | 1997-09-10 | Clive William Efford | Multi-engine drive unit |
WO1997034633A1 (en) | 1996-03-20 | 1997-09-25 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
EP1186300A1 (en) | 1996-03-20 | 2002-03-13 | Bristol-Myers Squibb Company | Pharmaceutical compositions useful for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways |
US7381407B1 (en) | 1996-03-25 | 2008-06-03 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
DK0914155T3 (da) | 1996-03-25 | 2006-06-26 | Medarex Inc | Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen |
US6150508A (en) | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6962981B1 (en) | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
DE19613691A1 (de) | 1996-04-05 | 1997-10-09 | Boehringer Ingelheim Int | Arzneimittel für die Behandlung von Tumorerkrankungen |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
CA2258721C (en) | 1996-07-12 | 2014-09-09 | Genentech, Inc. | Chimeric heteromultimer adhesins |
CA2267620A1 (en) | 1996-07-16 | 1998-01-22 | Andreas Pluckthun | Immunoglobulin superfamily domains and fragments with increased solubility |
WO1998003670A1 (en) | 1996-07-23 | 1998-01-29 | Tanox Pharma B.V. | Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways |
US5846948A (en) | 1996-08-30 | 1998-12-08 | Arch Development Corporation | Herpes simplex virus ORF P is a repressor of viral protein synthesis |
ATE218143T1 (de) | 1996-09-03 | 2002-06-15 | Gsf Forschungszentrum Umwelt | Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität |
GB9618477D0 (en) | 1996-09-04 | 1996-10-16 | Univ Leeds | Gene therapy |
US5972361A (en) | 1996-10-25 | 1999-10-26 | The Procter & Gamble Company | Cleansing products |
DE19651443A1 (de) | 1996-12-11 | 1998-06-18 | Hoechst Ag | Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme |
EP0860445A1 (en) | 1997-02-18 | 1998-08-26 | Hoechst Aktiengesellschaft | New nucleotide sequences for the cell cycle regulated expression of structural genes |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
WO1998040088A1 (en) | 1997-03-11 | 1998-09-17 | Les Laboratoires Aeterna Inc. | Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents |
CA2284211A1 (en) | 1997-03-20 | 1998-09-24 | University Of Washington | Solvent for biopolymer synthesis, solvent microdroplets and methods of use |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
AU740284B2 (en) | 1997-06-13 | 2001-11-01 | Genentech Inc. | Stabilized antibody formulation |
PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
WO1999002567A2 (en) | 1997-07-08 | 1999-01-21 | Board Of Regents, The University Of Texas System | Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
US6383746B1 (en) | 1997-10-23 | 2002-05-07 | The United States Of America As Represented By The Department Of Health And Human Services | Functional promoter for CCR5 |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6383811B2 (en) | 1997-12-30 | 2002-05-07 | Mirus Corporation | Polyampholytes for delivering polyions to a cell |
DK1049787T3 (da) | 1998-01-23 | 2005-04-04 | Vlaams Interuniv Inst Biotech | Antistofderivater med flere anvendelsesmuligheder |
AU3295299A (en) | 1998-02-19 | 1999-09-06 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
EP1060194A1 (en) | 1998-02-25 | 2000-12-20 | Lexigen Pharmaceuticals Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US6383481B1 (en) | 1998-03-30 | 2002-05-07 | Japan Immunoresearch Laboratories Co., Ltd. | Method for transplantation of hemopoietic stem cells |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
AU3655899A (en) | 1998-04-20 | 1999-11-08 | Regents Of The University Of California, The | Modified immunoglobulin molecules and methods for use thereof |
EP1073721B1 (en) | 1998-04-22 | 2005-08-31 | Genvec, Inc. | Efficient purification of adenovirus |
GB9809280D0 (en) | 1998-04-30 | 1998-07-01 | Rpms Technology Ltd | Immunosupression |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
AU5203199A (en) | 1998-05-26 | 1999-12-13 | Procter & Gamble Company, The | Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system |
US7405320B2 (en) | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
US7052872B1 (en) | 1999-06-22 | 2006-05-30 | Immunomedics, Inc. | Bi-specific antibodies for pre-targeting diagnosis and therapy |
US7833528B2 (en) | 1998-06-22 | 2010-11-16 | Immunomedics, Inc. | Use of multispecific, non-covalent complexes for targeted delivery of therapeutics |
AU760854B2 (en) | 1998-06-22 | 2003-05-22 | Immunomedics Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
ES2188202T3 (es) | 1998-07-13 | 2003-06-16 | Univ Texas | Metodos de tratamiento para el cancer usando conjugados terapeuticos que se enlazan con aminofosfolipidos. |
US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
DE69911793T2 (de) | 1998-07-28 | 2004-08-12 | Micromet Ag | Heterominikörper |
DK1974747T3 (da) | 1998-08-11 | 2012-09-17 | Biogen Idec Inc | Kombinationsterapier for B-celle-lymfomer omfattende indgivelse af anti-CD20-antistof |
WO2000011149A1 (en) | 1998-08-24 | 2000-03-02 | Uab Research Foundation | Methods of producing high titer recombinant adeno-associated virus |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6197294B1 (en) | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
WO2000027885A1 (fr) | 1998-11-05 | 2000-05-18 | Kyowa Hakko Kogyo Co., Ltd. | Nouveau popypeptide chimerique |
KR20010103655A (ko) | 1998-11-09 | 2001-11-23 | 케네쓰 제이. 울코트 | 키메라 항-cd20항체를 이용한 순환성 종양세포와관련된 혈액학적 악성종양의 치료법 |
PT1131096E (pt) | 1998-11-09 | 2010-04-14 | Biogen Idec Inc | Tratamento com anticorpo anti-cd20 de pacientes beneficiários de transplante de medula óssea ou transplante de células estaminais de sangue periférico |
US6380371B1 (en) | 1998-12-10 | 2002-04-30 | The Regents Of The University Of California | Endoglycan: a novel protein having selectin ligand and chemokine presentation activity |
MXPA01007170A (es) | 1999-01-15 | 2002-07-30 | Genentech Inc | Variantes de polipeptidos con funcion efectora alterada. |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
JP2002536968A (ja) | 1999-01-29 | 2002-11-05 | イムクローン システムズ インコーポレイティド | Kdrに特異的な抗体およびその使用 |
EP1035172A3 (en) | 1999-03-12 | 2002-11-27 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
US6383753B1 (en) | 1999-03-31 | 2002-05-07 | Regents Of The University Of Michigan | Yeast mammalian regulators of cell proliferation |
WO2000064954A1 (en) | 1999-04-22 | 2000-11-02 | Vanderbilt University | Polymeric encapsulation system promoting angiogenesis |
GB9909925D0 (en) | 1999-04-29 | 1999-06-30 | Pharmacia & Upjohn Spa | Combined preparations comprising anthracycline derivatives |
DE60024436T2 (de) | 1999-05-07 | 2006-08-17 | Genentech, Inc., South San Francisco | Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden |
US7074403B1 (en) | 1999-06-09 | 2006-07-11 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target B-cells |
KR20020018197A (ko) | 1999-05-19 | 2002-03-07 | 추후보정 | Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비 |
ITMI991299A1 (it) | 1999-06-11 | 2000-12-11 | Consiglio Nazionale Ricerche | Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite |
US6380382B1 (en) | 1999-06-30 | 2002-04-30 | Millennium Pharmaceuticals, Inc. | Gene encoding a protein having diagnostic, preventive, therapeutic, and other uses |
DE19930748C2 (de) | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
JP2003528805A (ja) | 1999-07-12 | 2003-09-30 | ジェネンテック・インコーポレーテッド | Cd20に結合するアンタゴニストを用いた異種抗原に対する免疫応答のブロッキング |
KR20020047098A (ko) | 1999-07-29 | 2002-06-21 | 추후제출 | HER2/neu에 대한 인간 모노클로날 항체 |
EP1210374B1 (en) | 1999-07-29 | 2006-10-11 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen |
KR100816958B1 (ko) | 1999-07-30 | 2008-03-26 | 메다렉스, 인코포레이티드 | 항-Fc 수용체 결합제를 포함하는 치료 화합물 |
US6451284B1 (en) | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
AU784971B2 (en) | 1999-08-11 | 2006-08-10 | Biogen Inc. | Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
WO2001013945A1 (en) | 1999-08-23 | 2001-03-01 | Biocrystal Ltd. | Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
IL149500A0 (en) | 1999-11-08 | 2002-11-10 | Idec Pharma Corp | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
US6380362B1 (en) | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
EP1257197A4 (en) | 2000-02-25 | 2008-07-16 | Health Research Inc | METHOD FOR THE TRANSDERMAL SAMPLING OF ANALYTES |
CA2404390A1 (en) | 2000-03-24 | 2001-10-04 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2 |
BR0109705A (pt) | 2000-03-31 | 2005-01-11 | Idec Pharma Corp | Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b |
SI2857516T1 (sl) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
US6518277B1 (en) | 2000-04-25 | 2003-02-11 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
CA2405632A1 (en) | 2000-04-25 | 2001-11-01 | Idec Pharmaceutical Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
AU6138301A (en) | 2000-05-08 | 2001-11-20 | Medarex Inc | Human monoclonal antibodies to dendritic cells |
AU2001264946A1 (en) | 2000-05-24 | 2001-12-03 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
CA2411102A1 (en) | 2000-06-20 | 2001-12-27 | Idec Pharmaceutical Corporation | Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
AU2001270134B2 (en) | 2000-06-22 | 2006-06-15 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
CN1451043A (zh) | 2000-06-29 | 2003-10-22 | 艾博特公司 | 双特异性抗体及其制备方法和用途 |
EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
IL153764A0 (en) | 2000-07-12 | 2003-07-06 | Idec Pharma Corp | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
IL152940A0 (en) | 2000-07-19 | 2003-06-24 | Orbotech Ltd | Apparatus and method for electrical testing of electrical circuits |
US20020025317A1 (en) | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
US20050054000A1 (en) | 2000-08-11 | 2005-03-10 | Stefan Dubel | Fv constructs with an influenceable affinity for a substance that is to be linked |
DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US20020128448A1 (en) | 2000-10-20 | 2002-09-12 | Idec Pharmaceuticals Corporation | Variant IgG3 Rituxan and therapeutic use thereof |
US7521054B2 (en) | 2000-11-17 | 2009-04-21 | The United States Of America As Represented By The Department Of Health And Human Services | Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the Fv to lower the isoelectric point |
RU2179862C1 (ru) | 2000-12-26 | 2002-02-27 | Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" | Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP2706116A1 (en) | 2001-01-17 | 2014-03-12 | Emergent Product Development Seattle, LLC | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
IL157142A0 (en) | 2001-01-29 | 2004-02-08 | Idec Pharma Corp | Modified antibodies and methods of use |
IL157274A0 (en) | 2001-02-12 | 2004-02-19 | Medarex Inc | Human monoclonal antibodies to fc alpha receptor (cd89) |
KR100900176B1 (ko) | 2001-03-07 | 2009-06-02 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술 |
US20050118164A1 (en) | 2001-03-09 | 2005-06-02 | William Herman | Targeted ligands |
DE60239931D1 (de) | 2001-04-02 | 2011-06-16 | Genentech Inc | Kombinationstherapie |
US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
US20040058445A1 (en) | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
EP2277542B1 (en) | 2001-06-01 | 2014-04-16 | Cornell Research Foundation Inc. | Modified antibodies to prostrate-specific membrane antigen and uses thereof |
US7666414B2 (en) | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
MXPA03011365A (es) | 2001-06-13 | 2005-03-07 | Genmab As | Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr). |
EP1404366A4 (en) | 2001-06-14 | 2006-06-07 | Intermune Inc | COMBINED THERAPY USING INTERFERON GAMMA AND SPECIFIC B-CELL ANTIBODIES |
AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
US20030026780A1 (en) | 2001-07-18 | 2003-02-06 | Hood Leroy E. | Innate immunity mediated methods of treating pathological conditions |
EP1427829A4 (en) | 2001-08-31 | 2005-10-12 | Abmaxis Inc | MULTIVALENT PROTEIN CONJUGATE WITH SEVERAL LIGANDEN BINDING RECORDORDOMAS |
EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
US20040044182A1 (en) | 2001-09-17 | 2004-03-04 | Hunt Joan S | Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g |
CA2461631A1 (en) | 2001-09-28 | 2003-04-03 | Elusys Therapeutics, Inc. | Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules |
EP1439857B1 (en) | 2001-10-12 | 2009-02-25 | Schering Corporation | USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES |
US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
AU2002356844C1 (en) | 2001-10-23 | 2010-03-04 | Amgen Fremont Inc. | PSMA antibodies and protein multimers |
DE10156482A1 (de) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
ES2283368T3 (es) | 2001-11-14 | 2007-11-01 | Affimed Therapeutics Ag | Anticuerpos biespecificos anti-cd19 y anti-cd16 y usos de los mismos. |
CN1189483C (zh) | 2001-11-23 | 2005-02-16 | 上海中信国健药业有限公司 | 人源化抗cd3单克隆抗体 |
RU2004122702A (ru) | 2001-12-26 | 2005-04-20 | Иммуномедикс, Инк. (Us) | Способы получения полиспецифичных, поливалентных средств из vh и vl доменов |
US7638326B2 (en) | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
KR20040077889A (ko) | 2002-01-28 | 2004-09-07 | 메다렉스, 인코포레이티드 | 전립선 특이적 막 항원 (psma)에 대한 인간모노클로날 항체 |
JP4498746B2 (ja) | 2002-02-14 | 2010-07-07 | イミューノメディクス、インコーポレイテッド | 抗cd20抗体およびその融合タンパク質ならびに使用法 |
JP2006502091A (ja) | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20030219436A1 (en) | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
CA2379586A1 (en) | 2002-04-10 | 2003-10-10 | William Herman | Fluid targeted ligands |
US7732149B2 (en) | 2002-04-26 | 2010-06-08 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening agonistic antibodies |
WO2003106622A2 (en) | 2002-05-30 | 2003-12-24 | The Children's Hospital Of Philadelphia | Methods for treatment of acute lymphocytic leukemia |
US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
JP2006512895A (ja) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
ATE536188T1 (de) | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
US20040091503A1 (en) | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
JP4790413B2 (ja) | 2002-10-08 | 2011-10-12 | イミューノメディクス、インコーポレイテッド | 抗体療法 |
SI1549344T1 (sl) | 2002-10-10 | 2015-05-29 | Merck Patent Gmbh | FARMACEVTSKI SESTAVKI PROTI RECEPTORJEM ErbB1 |
US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
EP2298806A1 (en) | 2002-10-16 | 2011-03-23 | Purdue Pharma L.P. | Antibodies that bind cell-associated CA 125/0722P and methods of use thereof |
PL216630B1 (pl) | 2002-10-17 | 2014-04-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
WO2004058171A2 (en) | 2002-12-20 | 2004-07-15 | Protein Design Labs, Inc. | Antibodies against gpr64 and uses thereof |
WO2004058191A2 (en) | 2002-12-20 | 2004-07-15 | Biogen Idec Ma Inc. | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
CN100402660C (zh) | 2002-12-23 | 2008-07-16 | 布里斯托尔-迈尔斯斯奎布公司 | 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高 |
CA2414148A1 (en) | 2002-12-30 | 2004-06-30 | William Herman | Targeted ligands |
US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7811564B2 (en) | 2003-01-28 | 2010-10-12 | Proscan Rx Pharma | Prostate cancer diagnosis and treatment |
JP3803790B2 (ja) | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
EP1599504B1 (en) | 2003-02-25 | 2014-12-03 | Vaccibody AS | Modified antibody |
SI1629011T1 (sl) | 2003-05-31 | 2010-05-31 | Micromet Ag | Humane molekule za vezavo anti hu cd |
JP2008501621A (ja) | 2003-05-31 | 2008-01-24 | マイクロメット アクツィエン ゲゼルシャフト | B細胞関連疾患を処置するための二重特異性抗cd3、抗cd19抗体構築物を含む薬学的組成物 |
US20050008649A1 (en) | 2003-06-02 | 2005-01-13 | University Of Miami | Chimeric molecules and methods of use |
CN1279056C (zh) | 2003-06-06 | 2006-10-11 | 马菁 | 肿瘤相关抗原sm5-1的特异性抗体及其应用 |
CA2529027C (en) | 2003-06-13 | 2013-09-10 | Immunomedics, Inc. | D-amino acid peptides |
EP1641826A2 (en) | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
US20050100543A1 (en) | 2003-07-01 | 2005-05-12 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
AU2004263538B2 (en) | 2003-08-08 | 2009-09-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
DK1673398T3 (da) | 2003-10-16 | 2011-04-18 | Micromet Ag | Multispecifikke, deimmuniserede CD3-bindere |
ES2372495T3 (es) | 2003-11-13 | 2012-01-20 | Hanmi Holdings Co., Ltd | Método para la producción en masa de la región constante de inmunoglobulina. |
ES2341252T3 (es) | 2003-11-28 | 2010-06-17 | Micromet Ag | Composiciones que comprenden polipeptidos. |
KR100956913B1 (ko) | 2003-12-19 | 2010-05-11 | 제넨테크, 인크. | 치료제로서 유용한 일가 항체 단편 |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
WO2005070456A2 (en) | 2004-01-09 | 2005-08-04 | Millennium Pharmaceuticals, Inc. | Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies |
WO2005070966A2 (en) | 2004-01-16 | 2005-08-04 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
SI1716178T1 (sl) | 2004-02-16 | 2010-11-30 | Micromet Ag | Manj imunogene vezne molekule |
JP4939397B2 (ja) | 2004-03-30 | 2012-05-23 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュ ユニバーシティ オブ エルサレム | アレルギー性反応に関与する細胞を標的化するための二重特異性抗体、ならびにその組成物および使用 |
US7910693B2 (en) | 2004-04-19 | 2011-03-22 | Proscan Rx Pharma Inc. | Prostate cancer diagnosis and treatment |
EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
CA2568661A1 (en) | 2004-06-03 | 2006-01-05 | Medarex, Inc. | Human monoclonal antibodies to fc gamma receptor i (cd64) |
US20070237712A1 (en) | 2004-06-14 | 2007-10-11 | Rajasekaran Ayyappan K | Methods of Redistributing Apical Target Antigens to Detect and Treat Cellular Proliferative Disease |
US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
US8518403B2 (en) | 2004-07-16 | 2013-08-27 | Amgen Research (Munich) Gmbh | Expression-enhanced polypeptides |
JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
MX2007000921A (es) | 2004-07-22 | 2007-11-09 | Univ Erasmus Medical Ct | Moleculas de union. |
MX2007001638A (es) | 2004-08-11 | 2009-02-12 | Trubion Pharmaceuticals Inc | Proteinas de fusion del dominio de unión. |
JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
US8066989B2 (en) | 2004-11-30 | 2011-11-29 | Trion Pharma Gmbh | Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy |
ATE525400T1 (de) | 2004-12-01 | 2011-10-15 | Trion Pharma Gmbh | Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie |
AU2005313971B2 (en) | 2004-12-08 | 2011-10-13 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
CA2594356C (en) | 2005-01-05 | 2018-07-17 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
KR100616666B1 (ko) | 2005-01-27 | 2006-08-28 | 삼성전기주식회사 | 카본나노튜브에 구아니딘기를 형성하는 방법,구아니딘기가 형성된 카본나노튜브를 기판에 부착하는방법 및 이에 따라 제조된 카본나노튜브 및 기판 |
EP1851251A2 (en) | 2005-02-18 | 2007-11-07 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
KR20070115967A (ko) | 2005-02-18 | 2007-12-06 | 메다렉스, 인코포레이티드 | 전립선 특이 막 항원(psma)에 대한 인간 모노클로날항체 |
GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
CA2606081C (en) | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
US8034902B2 (en) | 2005-05-04 | 2011-10-11 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against CD55 and CD59 and uses thereof |
US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
US7736647B2 (en) | 2005-06-15 | 2010-06-15 | Monoclonal Antibodies Therapeutics | Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
DK1912677T3 (da) | 2005-06-20 | 2014-01-13 | Psma Dev Company L L C | PSMA-antistof-lægemiddel-konjugater |
WO2007014238A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | Single dose use of cd20-specific binding molecules |
US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
NI200800032A (es) | 2005-07-25 | 2009-03-23 | Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20 | |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2500352A1 (en) | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
AR056142A1 (es) | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
CA2634387C (en) | 2005-12-20 | 2015-11-24 | Morphosys Ag | Novel collection of hcdr3 regions and uses therefor |
WO2007095338A2 (en) | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Functional antibodies |
AU2007233831B2 (en) | 2006-03-30 | 2013-02-14 | Glaxo Group Limited | Antibodies against amyloid-beta peptide |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
JP2009539841A (ja) | 2006-06-06 | 2009-11-19 | トラークス,インコーポレイテッド | 自己免疫疾患の治療における抗cd3抗体の投与 |
MX2008015524A (es) | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
WO2008051448A2 (en) | 2006-10-19 | 2008-05-02 | Tolerx, Inc. | Methods and compositions for efficient removal of protein a from binding molecule preparations |
JP2010507394A (ja) | 2006-10-24 | 2010-03-11 | トルービオン ファーマスーティカルズ インコーポレイテッド | 改良免疫糖タンパク質のための物質および方法 |
US7846434B2 (en) | 2006-10-24 | 2010-12-07 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
EP2094302A4 (en) | 2006-12-21 | 2010-12-08 | Macrogenics Inc | METHODS FOR THE TREATMENT OF LADA-LIKE DIABETES AND OTHER AUTOIMMUNE DIABETES OF THE ADULT USING IMMUNOSUPPRESSANT MONOCLONAL ANTIBODIES HAVING REDUCED TOXICITY |
KR101626988B1 (ko) | 2007-04-03 | 2016-06-02 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 이중특이적인 결합제들 |
WO2008131242A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
WO2008153636A1 (en) | 2007-05-04 | 2008-12-18 | Cellsignaling Technology, Inc. | Phospho-specific antibodies to p13k regulatory subunit and uses thereof |
MX2009012066A (es) | 2007-05-09 | 2009-11-19 | Novartis Ag | Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k. |
BRPI0811857A2 (pt) | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
WO2008150485A2 (en) | 2007-05-29 | 2008-12-11 | Wyeth | Erbb2 binding proteins and use thereof |
CN101679456B (zh) | 2007-06-12 | 2012-09-05 | 霍夫曼-拉罗奇有限公司 | 噻唑并嘧啶类和它们作为磷脂酰肌醇3-激酶的抑制剂的应用 |
WO2008152394A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Pharmaceutical compounds |
WO2008152387A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Quinazoline derivatives as pi3 kinase inhibitors |
BRPI0814060A2 (pt) | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal |
AU2008282729B2 (en) | 2007-08-01 | 2015-07-16 | Scott & White Healthcare | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
EP2033657A1 (de) | 2007-09-04 | 2009-03-11 | Trion Pharma Gmbh | Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination |
BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
US20100204222A1 (en) | 2007-09-17 | 2010-08-12 | GlaxoSmithKline, LLC | Pyridopyrimidine derivatives as p13 kinase inhibitors |
CN101932587A (zh) | 2007-09-24 | 2010-12-29 | 吉宁特有限公司 | 噻唑并嘧啶pi3k抑制剂化合物及使用方法 |
HUE025976T2 (en) | 2007-09-27 | 2016-05-30 | Fund Centro Nac De Investig Oncologicas Carlos Iii | Imidazolothiadiazoles for use as protein kinase inhibitors |
WO2009046294A2 (en) | 2007-10-03 | 2009-04-09 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
DK2209786T3 (da) | 2007-10-05 | 2013-06-03 | Verastem Inc | Pyrimidinsubstituerede purinderivater |
US20110009403A1 (en) | 2007-10-05 | 2011-01-13 | S*Bio Pte Ltd. | 2-morpholinylpurines as inhibitors of pi3k |
AU2008312631A1 (en) | 2007-10-16 | 2009-04-23 | Wyeth Llc | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors |
EP2211615A4 (en) | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS |
CN101835779B (zh) | 2007-10-26 | 2014-01-29 | 霍夫曼-拉罗奇有限公司 | 作为pi3激酶抑制剂的嘌呤衍生物 |
GB0721095D0 (en) | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
WO2009058361A1 (en) | 2007-10-31 | 2009-05-07 | Dynavax Technologies Corp. | Inhibition of type i ifn production |
WO2009059030A1 (en) | 2007-10-31 | 2009-05-07 | Burnham Institute For Medical Research | Pyrazole derivatives as kinase inhibitors |
EP2220089A4 (en) | 2007-11-13 | 2011-10-26 | Icos Corp | HEMMER OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE-DELTA |
WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
WO2009070524A1 (en) | 2007-11-27 | 2009-06-04 | Wyeth | Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors |
US8865699B2 (en) | 2007-11-27 | 2014-10-21 | Cellzome Ltd. | Amino triazoles as PI3K inhibitors |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
SI2132228T1 (sl) | 2008-04-11 | 2011-10-28 | Emergent Product Dev Seatle | CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom |
US20110189093A1 (en) | 2008-04-14 | 2011-08-04 | Proscan Rx Pharma | Prostate specific membrane antigen antibodies and antigen binding fragments |
ITTO20080313A1 (it) | 2008-04-22 | 2009-10-23 | Marco Colombatti | Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi |
MX2011000071A (es) | 2008-07-02 | 2011-05-03 | Emergent Product Dev Seattle | Inmunoterapeuticos de interleucina-6 (il6). |
AU2009266873A1 (en) | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | TGF-beta antagonist multi-target binding proteins |
NZ590668A (en) | 2008-07-02 | 2012-12-21 | Emergent Product Dev Seattle | TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINS |
WO2010014629A1 (en) | 2008-07-28 | 2010-02-04 | Trubion Pharmaceuticals, Inc. | Multi-specific binding proteins targeting b cell disorders |
DK2326350T3 (da) | 2008-09-08 | 2013-12-16 | Psma Dev Company L L C | Forbindelser til at dræbe psma-udtrykkende, taxanresistente cancerceller |
EP2342231A1 (en) | 2008-09-26 | 2011-07-13 | Roche Glycart AG | Bispecific anti-egfr/anti-igf-1r antibodies |
US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
KR101820535B1 (ko) | 2008-10-01 | 2018-01-19 | 암젠 리서치 (뮌헨) 게엠베하 | 종간특이적 psmaxcd3 이중특이적 단일쇄 항체 |
EP2352763B2 (en) | 2008-10-01 | 2022-09-21 | Amgen Research (Munich) GmbH | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
ES2657220T3 (es) | 2008-10-02 | 2018-03-02 | Aptevo Research And Development Llc | Proteínas de unión multi-diana antagonistas de CD86 |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
US20110217302A1 (en) | 2008-10-10 | 2011-09-08 | Emergent Product Development Seattle, Llc | TCR Complex Immunotherapeutics |
US20100135900A1 (en) | 2008-11-13 | 2010-06-03 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic combination therapies and uses thereof |
HUE062339T2 (hu) | 2009-02-13 | 2023-10-28 | Immunomedics Inc | Sejten belül hasítható kötést tartalmazó immunkonjugátumok |
CA2758751C (en) | 2009-04-14 | 2017-03-21 | Proscan Rx Pharma Inc. | Antibodies against prostate specific membrane antigen |
WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
CN102448985B (zh) | 2009-05-27 | 2015-08-05 | 霍夫曼-拉罗奇有限公司 | 三或四特异性抗体 |
KR101962476B1 (ko) | 2009-07-03 | 2019-03-26 | 아비펩 피티와이 리미티트 | 면역성 접합체 및 그 제조방법 |
EP2516462B1 (en) | 2009-12-23 | 2015-05-06 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
WO2011079308A2 (en) | 2009-12-23 | 2011-06-30 | Emergent Product Development Seattle, Llc | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
EP3112382A1 (en) | 2009-12-29 | 2017-01-04 | Emergent Product Development Seattle, LLC | Heterodimer binding proteins and uses thereof |
TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
WO2011123830A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
SG187682A1 (en) | 2010-08-02 | 2013-03-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
TWI638833B (zh) | 2010-11-30 | 2018-10-21 | 中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
WO2012088290A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
EP2683735A1 (en) | 2011-03-10 | 2014-01-15 | HCO Antibody, Inc. | Bispecific three-chain antibody-like molecules |
US20140112926A1 (en) | 2011-03-16 | 2014-04-24 | Amgen Inc. | Fc VARIANTS |
TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
CA2833019A1 (en) | 2011-04-22 | 2012-10-26 | Emergent Product Development Seattle, Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
CN107936121B (zh) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
EP2525222A1 (en) | 2011-05-17 | 2012-11-21 | Markus M. Heiss | Initial relative lymphocyte count as predictive biomarker |
CN107586340B (zh) | 2011-08-23 | 2022-01-21 | 罗切格利卡特公司 | 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法 |
LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
CN104203981A (zh) | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
KR101963230B1 (ko) | 2011-12-26 | 2019-03-29 | 삼성전자주식회사 | 복수개의 단일 항체를 포함하는 단백질 복합체 |
PL2802607T3 (pl) | 2012-01-13 | 2018-03-30 | Julius-Maximilians-Universität Würzburg | Dwuskładnikowa komplementacja funkcjonalna wywoływana przez podwójny antygen |
WO2013121175A1 (en) | 2012-02-16 | 2013-08-22 | Ucl Business Plc | Lysosome-cleavable linker |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
WO2013128027A1 (en) | 2012-03-01 | 2013-09-06 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
US20150031861A1 (en) | 2012-03-09 | 2015-01-29 | Ucl Business Plc | Chemical Modification of Antibodies |
CA2870545A1 (en) | 2012-04-20 | 2013-10-24 | Emergent Product Development Seattle, Llc | Cd3 binding polypeptides |
RU2014145633A (ru) | 2012-05-14 | 2016-07-10 | Дженентек, Инк. | Композиции и способы для диагностики и лечения опухолей |
US9745381B2 (en) | 2012-05-18 | 2017-08-29 | Scott & White Healthcare (Swh) | Bispecific scFv immunofusion (BIf) |
US20130309234A1 (en) | 2012-05-18 | 2013-11-21 | Trion Pharma Gmbh | Correlation of de novo-induced tumor-associated humoral immune responses with improved clinical outcome |
CN104363919A (zh) | 2012-06-01 | 2015-02-18 | Ibc药品公司 | 具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物 |
BR112015000167B1 (pt) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
CN104640562A (zh) | 2012-07-13 | 2015-05-20 | 酵活有限公司 | 包含抗-cd3构建体的双特异性不对称异二聚体 |
CN109513003A (zh) | 2012-08-14 | 2019-03-26 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
WO2014043208A1 (en) | 2012-09-11 | 2014-03-20 | Medivation Prostate Therapeutics, Inc. | Formulations of enzalutamide |
KR20140036905A (ko) | 2012-09-18 | 2014-03-26 | 삼성전자주식회사 | 이중특이 항체를 포함하는 단백질 복합체 |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
EP2904016B1 (en) | 2012-10-08 | 2018-11-14 | Roche Glycart AG | Fc-free antibodies comprising two fab-fragments and methods of use |
KR101911438B1 (ko) | 2012-10-31 | 2018-10-24 | 삼성전자주식회사 | 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법 |
CN112079929A (zh) | 2012-11-21 | 2020-12-15 | 武汉友芝友生物制药有限公司 | 双特异性抗体 |
US20140377269A1 (en) | 2012-12-19 | 2014-12-25 | Adimab, Llc | Multivalent antibody analogs, and methods of their preparation and use |
US10329350B2 (en) | 2012-12-26 | 2019-06-25 | Industrial Technology Research Institute | Method for producing a multivalent fab fragment with collagen-like peptide |
EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
WO2014143807A2 (en) | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
WO2014151438A1 (en) | 2013-03-15 | 2014-09-25 | Emergent Product Development Seattle, Llc | Multispecific anti-cd37 antibodies and related compositions and methods |
WO2016014974A2 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
WO2016094873A2 (en) * | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
WO2016130819A2 (en) | 2015-02-11 | 2016-08-18 | Emergent Product Development Seattle Llc | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins |
-
2016
- 2016-09-21 WO PCT/US2016/052942 patent/WO2017053469A2/en active Application Filing
- 2016-09-21 JP JP2018513821A patent/JP7002446B2/ja active Active
- 2016-09-21 CN CN201680054840.3A patent/CN108367004B/zh active Active
- 2016-09-21 EP EP16849533.1A patent/EP3352760A4/en active Pending
- 2016-09-21 BR BR112018005573A patent/BR112018005573A2/pt active Search and Examination
- 2016-09-21 SG SG10202002577XA patent/SG10202002577XA/en unknown
- 2016-09-21 CA CA2999138A patent/CA2999138A1/en active Granted
- 2016-09-21 AU AU2016326449A patent/AU2016326449A1/en active Pending
- 2016-09-21 KR KR1020187009336A patent/KR20180053322A/ko not_active Application Discontinuation
- 2016-09-21 UA UAA201803341A patent/UA126278C2/uk unknown
- 2016-09-21 EA EA201890613A patent/EA201890613A1/ru unknown
- 2016-09-21 MX MX2018003292A patent/MX2018003292A/es unknown
- 2016-09-21 US US15/761,499 patent/US11352426B2/en active Active
- 2016-09-21 MY MYPI2018701059A patent/MY197562A/en unknown
-
2018
- 2018-03-09 PH PH12018500520A patent/PH12018500520A1/en unknown
- 2018-03-18 IL IL258202A patent/IL258202B2/en unknown
- 2018-04-13 ZA ZA2018/02440A patent/ZA201802440B/en unknown
- 2018-04-17 CO CONC2018/0004094A patent/CO2018004094A2/es unknown
- 2018-08-21 HK HK18110709.1A patent/HK1251175A1/zh unknown
- 2018-08-29 HK HK18111095.1A patent/HK1251480A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014517844A (ja) | 2011-05-21 | 2014-07-24 | マクロジェニクス,インコーポレーテッド | ヒト及び非ヒトcd3に結合可能なcd3結合分子 |
WO2014072888A1 (en) | 2012-11-07 | 2014-05-15 | Pfizer Inc. | Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates |
WO2014106602A1 (en) | 2013-01-02 | 2014-07-10 | Glenmark Pharmaceuticals S.A. | Antibodies that bind to tl1a and their uses |
Non-Patent Citations (2)
Title |
---|
Nainong Li ,PNAS,2008年,vol.105,no.12,p.4796-4801 |
熊谷 泉,リンパ球とがん細胞を認識するヒト型二重特異性抗体,Drug Delivery System,2008年,23-5,p.518-525 |
Also Published As
Publication number | Publication date |
---|---|
JP2018531000A (ja) | 2018-10-25 |
MY197562A (en) | 2023-06-23 |
EA201890613A1 (ru) | 2018-10-31 |
WO2017053469A3 (en) | 2017-05-04 |
HK1251175A1 (zh) | 2019-01-25 |
US11352426B2 (en) | 2022-06-07 |
IL258202A (en) | 2018-05-31 |
US20180273622A1 (en) | 2018-09-27 |
UA126278C2 (uk) | 2022-09-14 |
PH12018500520A1 (en) | 2018-08-29 |
IL258202B2 (en) | 2023-02-01 |
EP3352760A2 (en) | 2018-08-01 |
ZA201802440B (en) | 2023-05-31 |
HK1251480A1 (zh) | 2019-02-01 |
IL258202B (en) | 2022-10-01 |
CO2018004094A2 (es) | 2018-07-10 |
EP3352760A4 (en) | 2019-03-06 |
SG10202002577XA (en) | 2020-04-29 |
BR112018005573A2 (pt) | 2019-01-22 |
WO2017053469A2 (en) | 2017-03-30 |
CN108367004B (zh) | 2022-09-13 |
KR20180053322A (ko) | 2018-05-21 |
CA2999138A1 (en) | 2017-03-30 |
CN108367004A (zh) | 2018-08-03 |
MX2018003292A (es) | 2018-08-01 |
AU2016326449A1 (en) | 2018-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7002446B2 (ja) | Cd3結合ポリペプチド | |
JP2018531000A6 (ja) | Cd3結合ポリペプチド | |
US11939392B2 (en) | CD123 binding proteins and related compositions and methods | |
JP6708635B2 (ja) | CD3εおよびROR1に対する二特異性抗体 | |
US10202452B2 (en) | CD3 binding polypeptides | |
JP7369113B2 (ja) | 癌胎児性抗原結合タンパク質、関連する化合物および方法 | |
AU2012245260B2 (en) | Prostate-specific membrane antigen binding proteins and related compositions and methods | |
US20180022819A1 (en) | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins | |
CA2999138C (en) | Cd3 binding polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190920 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190920 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201027 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210125 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210326 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210427 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210525 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210825 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211022 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211119 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211221 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211227 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7002446 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |